XNAS · Drug Manufacturers - Specialty & Generic
Last stored close · Sep 18, 2026
Close · Sep 18, 2026
$66.88-2.21%
Model Target
available with Pro
Implied upside
vs the model target
Valuation methods
the methods behind the target
TickerWhale Score
53/100
Moderate
Score components
TickerWhale View
Liquidia scores 53 out of 100 overall, which we rate moderate. Quality & growth is its strongest area and Valuation its weakest.
What helps
- Quality & growth
- Risk
What to watch
- Technical
- Valuation
Quality & growth
30%99Strong
- Revenue growth 2232.7%
- EPS growth n/a
Valuation
25%8Weak
- P/E 48.9
- EV/Sales 14.8
Price history
Intraday to five-year windows are free with an account
Members switch between 1D, 1M, 6M, 1Y, 2Y and 5Y and see the live price. Signed out, this is the one-year stored series the technicals below are computed from.
Market intelligence
Peer position
#84 / 139sector rank by TickerWhale Score
TickerWhale Score 53 vs sector average 55.1 (-2.1)
Revenue growth (industry)Top 11%
Gross margin (industry)Top 22%
Return on equity (industry)Top 14%
P/E (industry)Pricier than 71%
Technical analysis
our read · what classic indicators sayTickerWhale technical read
41/100Weak vs universe
Ranks 41st of 100 covered names on our technical composite — the composite itself scores 43/100 · 25% of the TickerWhale Score
Classic chart indicators
Strong Sell
1 buy · 4 sell · 3 neutral of 8 votes
TickerWhale rates LQDA's technical setup weak — 41st percentile of the covered universe. Classic chart indicators lean sell, pointing the same way.
Moving averages
2 / 9constructive
- vs 200-day+26.2%
- vs 50-day-12.4%
Momentum
Mixed
- RSI (14)41 · neutral
- Stochasticsell
- CCIneutral
- Williams %Rneutral
Trend
Mixed
- ADX (14) trend strength24· trending
- MACD (12,26,9)buy(histogram 0.325)
How the classic verdict is reached
Moving averages (9) agree on sell — 2 buy vs 7 sell — and carry one vote between them.
Oscillators (7) vote individually: 1 buy · 3 sell · 3 neutral.
Result — 1 buy vs 4 sell of 8 votes = Strong Sell. Neutral votes never decide the verdict.
Fundamentals & valuation
2026-09-18 · revised_latestValuation multiples
- P/E (TTM)48.9
- P/S (TTM)15.0
- P/B34.8
- EV/EBITDA—
- EV/Sales14.8
- PEG—
Profitability & returns
- Gross margin92.5%
- Net margin30.7%
- ROE91.3%
- Debt/Equity0.90
Growth
- Revenue growth (YoY)2232.7%
- EPS growth (YoY)—
Green favourable · red stretched — multiples and D/E vs industry peers, margins and growth vs absolute thresholds.
Market capitalisation — $6.8B
Fundamentals history
Reported statement totals across recent periods.
Fundamentals are stored revised/latest (ADR-009): each period reflects the most recent vendor refresh, NOT point-in-time as-reported values. Do not use this series to claim what was known on a past date.
Model Target
Model Target is a Pro feature
Scores, factors and technicals stay free. The model's price target is part of TickerWhale Pro.
The Model Target is a TickerWhale Pro feature
A target exists for this name — the model priced it in the latest nightly run. Pro members see the target, its range and the methods behind it; one name's target is free every trading day.
Or see the current free one: MU →
Peers
| Company | Score | Pulse | P/E | P/E fwd | P/B | EV/Sales | Price | Chg | Estimate | Upside | Rev. gr. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| LQDACurrentLiquidia | 53 | 43 | 48.9 | — | 34.8 | 14.8 | $66.88 | -2.21% | +2232.7% | ||
| EXELExelixis | 81 | 80 | 17.6 | — | 8.2 | 6.1 | $58.36 | -0.22% | +9.2% | ||
| INCYIncyte | 81 | 76 | 16.2 | — | 4.1 | 3.8 | $125.31 | -1.81% | +26.9% | ||
| ACADAcadia Pharmaceuticals | 80 | 63 | 12.4 | — | 3.6 | 3.8 | $27.29 | -0.58% | +11.8% | ||
| OSCROscar Health Inc - | 78 | 67 | 19.5 | — | 5.2 | 0.5 | $32.13 | +0.47% | +43.1% | ||
| TGTXTG Therapeutics | 77 | 73 | 20.3 | — | 14.8 | 11.5 | $56.87 | +0.71% | +76.1% |
News, sentiment, the Street view and Ask Willy are free with an account
A free account shows the stories attached to this name, the Sentiment Signal breakdown, analyst consensus, the options read and the AI narration of the model output.